Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study

ConclusionsGalcanezumab was efficacious and well-tolerated in patients with episodic migraine from China, India and Russia, for up to 6  months.Trial registrationClinicalTrisABSTRACT_pals.gov NCT03963232, registered May 24, 2019.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research